| BMSLX | FSMDX | BMSLX / FSMDX | |
| Total Expense Ratio | 0.59 | 0.03 | 2,360% |
| Annual Report Gross Expense Ratio | 0.67 | 0.03 | 2,680% |
| Fund Existence | 9 years | 14 years | - |
| Gain YTD | 4.533 | 6.417 | 71% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 2.17B | 45B | 5% |
| Annual Yield % from dividends | 0.81 | 1.26 | 65% |
| Returns for 1 year | -7.80 | 1.94 | -402% |
| Returns for 3 years | 24.56 | 38.73 | 63% |
| Returns for 5 years | 21.60 | 48.13 | 45% |
| Returns for 10 years | N/A | 128.68 | - |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| FGSCX | 26.87 | 0.03 | +0.11% |
| Federated Hermes MDT Mid Cap Growth C | |||
| RYSVX | 208.74 | N/A | N/A |
| Rydex S&P SmallCap 600 Pure Value A | |||
| VEIGX | 37.81 | N/A | N/A |
| Vanguard Global ESG Select Stk Investor | |||
| IVGIX | 19.02 | -0.02 | -0.11% |
| VY® Invesco Growth and Income I | |||
| BRWCX | 26.59 | -0.30 | -1.12% |
| MFS Blended Research Growth Eq C | |||